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Abstract
Evolution by natural selection is the conceptual foundation for nearly every branch of biology and 
increasingly also for biomedicine and medical research. In cancer biology, evolution explains how 
populations of cells in tumors change over time. It is a fundamental question whether this 
evolutionary process is driven primarily by natural selection and adaptation or by other 
evolutionary processes such as founder effects and drift. In cancer biology, as in organismal 
evolutionary biology, there is controversy about this question and also about the use of adaptation 
through natural selection as a guiding framework for research. In this review, we discuss the 
differences and similarities between evolution among somatic cells versus evolution among 
organisms. We review what is known about the parameters and rate of evolution in neoplasms, as 
well as evidence for adaptation. We conclude that adaptation is a useful framework that accurately 
explains the defining characteristics of cancer. Further, convergent evolution through natural 
selection provides the only satisfying explanation both for how a group of diverse pathologies have 
enough in common to usefully share the descriptive label of “cancer” and for why this convergent 
condition becomes life-threatening.
Although evolutionary adaptation by somatic cells is different from adaptation by organisms, 
it is an important part of cancer biology and needs to be understood. One centrally important 
application lies in reconciling two major and contrasting patterns in cancer biology, which 
we refer to as trait “hallmarks” and molecular “snowflakes.” The first of these two patterns 
to be described was the striking consistency among different types of cancer at the level of 
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cell traits. Although they originate from different tissues and cell types, virtually all cancers 
consist of cells with the same essential “hallmark” traits (Hanahan and Weinberg 2000, 
2011). This quickly became one of the few organizing frameworks to impose order on the 
bewildering diversity of cancer. The superficially contrasting pattern that has since emerged 
from molecular analysis is that virtually any molecular category of cancers can, on closer 
inspection, be broken down into subcategories by looking for, and invariably finding, 
molecular variations. Indeed, molecular differences can usually be found between any two 
cases, leading to the impression that perhaps, like snowflakes, no two cancer cases are 
exactly alike (Kurzrock and Giles 2015).
The apparent contradiction between trait “hallmarks” and molecular “snowflakes” is 
resolved by understanding the underlying evolutionary and ecological process of cancer, as 
distinct from its static manifestations (Merlo et al. 2006; Pepper et al. 2014). A cancer is a 
dynamic population of abnormal somatic cells evolving through natural selection. In 
classical evolutionary biology, it is well understood that even when two such populations 
arise from different genetic backgrounds, and thus have few similarities at the molecular 
level, a shared ecological niche and its shared selective pressures can drive the process of 
evolutionary adaptation by natural selection toward the same traits, causing the two 
populations to converge onto those traits despite their different starting points and persistent 
molecular differences (Fig. 1).
In evolutionary biology, there has long been controversy over the power and limitations of 
the “adaptationist program” as a way to generate hypotheses and guide research (Gould and 
Lewontin 1979; Mayr 1983). The adaptationist approach emphasizes that natural selection 
leads populations to evolve functional adaptations. This is contrasted with a null model of 
neutral evolution and an approach that emphasizes the importance of constraints and side 
effects in influencing the evolutionary trajectory (Gould and Lewontin 1979). A similar 
debate is now present in cancer biology, with some investigators arguing against “excessive 
adaptationism,” partly on the grounds that a few decades is probably not long enough for 
cancer cells to evolve all their observed complex traits (Arnal et al. 2015). This debate can 
be summarized by two questions: First, are cancers characterized by natural selection or by 
neutral evolution? And, second, does somatic evolution produce complex and novel 
adaptations in cancer cells or does it simply remove or activate cell functions that are already 
encoded in the constitutive human genome?
In fact, these are false dichotomies. The apparent alternatives are both true. There is good 
evidence for both neutral evolution and natural selection in neoplasms, and the relative 
importance of the two probably changes during progression. Neoplastic cells produce 
complex and novel adaptations, often by removing or activating cell functions that are 
already in the human genome, but also sometimes through genetic novelties.
IS A HUMAN LIFETIME LONG ENOUGH FOR SOMATIC CELLS TO EVOLVE 
COMPLEX ADAPTATIONS?
One of the arguments against applying an adaptationist framework to cancer cells is that the 
scope of resulting adaptation may be limited because the human lifetime is too short for 
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complex cell adaptations to evolve de novo (Arnal et al. 2015). In this section, we examine 
the validity of this claim by reviewing the literature on the pace of evolutionary change in 
neoplasms. The rate of evolutionary change depends critically on parameters such as 
mutation rate, population size, and population turnover rate (inverse of cell generation time). 
Considering these factors suggests that somatic cell evolution can be much more rapid than 
evolution among multicellular organisms. Many cancer cells have the capacity to divide 
daily, evolve over a period of decades, and comprise populations numbering in the billions to 
trillions (Table 1). Based solely on population size and generation time, there are more 
reproductive events among the cells within one host individual than there have been among 
individuals in the entire history of the human species. Each such reproductive event is an 
opportunity for mutation and selective reproduction and, thus, for adaptive evolution.
Regarding a third crucial parameter of evolution, mutation rate, current estimates suggest 
that every base pair in the cancer genome is probably mutated in some cell, in every cell 
generation within a neoplasm (Table 1). This too suggests that somatic evolution can be 
rapid and that its molecular bases can be diverse, as the same gene may mutate 
independently multiple times within the same neoplasm. This appears to be true empirically 
(Anderson et al. 2011; Gerlinger et al. 2012, 2014; Kovac et al. 2015; Yates et al. 2015). In 
fact, the exact same mutation is seen to occur multiple times in the same neoplasm, causing 
multiple independent origins, or “homoplasy” (e.g., Shpak et al. 2015). This mutational 
redundancy also explains why there are likely to be multiple mechanisms of acquired 
resistance available for a response to the selection imposed by therapy (Murugaesu et al. 
2015).
In neoplasms, the number of cell generations per unit time may be high and only loosely 
related to the size of the tumor, because of high levels of apoptosis and rapid cell turnover 
(Lowe and Lin 2000; Liu et al. 2001). To estimate number of cell generations, the total 
number of cell divisions necessary to generate a tumor’s size must be integrated with the 
rate of cell death.
Another factor accelerating cellular evolution in neoplasms is that it can be driven not only 
by genetic, but also by epigenetic modifications. Epigenetic changes are subject to somatic 
natural selection because they are heritable across mitosis and can affect the fitness of the 
cell by changing its phenotype. The rate of epigenetic modifications is sometimes much 
higher than the rate of genetic mutations (Table 1) and so may be an important driver of 
evolution in neoplasms.
Taken together, all these considerations suggest that a human lifetime is sufficient for cells to 
evolve substantial adaptation. Large population sizes, short generation time, and high 
mutation rates all contribute to a rapid pace of evolution within neoplasms. In the framework 
of the adaptationism debate, many of the resulting complex traits can legitimately be viewed 
either as novel (in their current context) or as recapitulations of traits that are normally 
functional for the multicellular organism in different cell types or at different stages of 
development.
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Also increasing the potential for cancer cell adaptation is the fact that cancer cells have 
access to a large toolbox of adaptations and traits from the human genome that are available 
for their use, alteration, and repurposing. For example, the normal conditional response of 
changing cell behavior and migrating away from regions of depleted resources is already 
built into the human genome. Hypoxia can trigger cell motility via HIF1α (Semenza 2012). 
A neoplastic cell need only activate and repurpose this pathway to acquire the cell motility 
behavior that is central to tissue invasion and metastasis (Chen et al. 2011; Aktipis et al. 
2012). We suggest that the large size and complexity of the human genome imparts 
substantial evolvability through repurposing for cell-level fitness advantage.
Also related to the finite human life span, some investigators have mistakenly argued that the 
potential for adaptation is limited by the fact that most cancers will die with their host 
(Davies and Lineweaver 2011; Arnal et al. 2015). In fact, this does not preclude adaptations 
in a neoplasm during the lifetime of the host. Even if those cancer adaptations will cause the 
cancer’s extinction, that does not prevent the mechanics of natural selection or otherwise 
impinge on cancer adaptation. The idea that cancer cells or the mutated genes that determine 
their behavior are not involved in an evolutionary process because they are destined to rapid 
extinction because of the host’s death (caused by themselves) is demonstrably wrong. So-
called “evolutionary suicide” through adaptive evolution is in fact a well-understood 
phenomenon with many examples (Ibrahim 2014). Adaptive cellular evolution is notoriously 
“shortsighted” regarding later consequences, including in particular harm to the host 
individual (Levin and Bull 1994).
IS ADAPTATION MORE OR LESS LIKELY IN CANCER CELLS BECAUSE OF 
DIFFERENCES BETWEEN ORGANISMAL AND SOMATIC EVOLUTION?
In addition to the finite life span of the host that is the “environment” of somatic cells, there 
are other important differences between somatic cellular versus organismal evolution, and 
understanding these differences can help us better answer the question of whether cancer 
cells can evolve adaptations via natural selection. Natural selection among multicellular 
organisms is typically a very slow process because of long generation times (compared with 
somatic cells) and small population sizes (compared with billions of cells in a growing 
neoplasm).
Factors that favor adaptation in multicellular organisms include their large diploid genomes 
and sexual reproduction. Sexual reproduction involves genomic recombination, which can 
contribute to genetic variation among individuals and remove deleterious mutations. In this 
regard, somatic cell evolution is more similar to evolution among single-cell organisms. Like 
somatic cells, many unicellular eukaryotes reproduce asexually and have large population 
sizes and short generation times. In contrast, somatic cells within a human host have huge 
diploid genomes that may allow them to evolve over shorter periods of time (15–60 years) 
(Meza et al. 2008; Yachida et al. 2010), despite the fact that there is currently little evidence 
of genomic recombination among cancer cells.
Another fundamental difference increasing the likelihood of adaptation by cancer cells lies 
in the initial state of the cell. Organisms have typically evolved to an adaptive fitness peak 
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(as shown in Fig. 1), so that most random mutations are detrimental, especially loss-of-
function mutations. In contrast, somatic cells start with many built-in constraints on cell 
survival and reproduction from the legacy of selection among multicellular organisms. In the 
abnormal context of selection among somatic cells, this puts them in a fitness pit rather than 
on a peak on the adaptive landscape. Random (epi)-mutations in a neoplastic cell can easily 
be beneficial, at least early in carcinogenesis, and can allow the neoplastic cell to quickly 
climb out of its fitness pit. For example, loss-of-function mutations that break the evolved 
cellular machinery that normally suppresses cellular proliferation, or supports apoptosis, 
would provide immediate fitness benefit to a somatic cell. The same reasoning applies to 
most of the cancer “hallmark” traits. This difference between organismal and somatic 
evolution should lead to more rapid early accumulation of adaptations in somatic evolution 
than in organismal evolution.
To sum up, some of the differences between somatic evolution and organismal evolution 
make the evolution of complex adaptations less likely in cancer than in multicellular 
organisms, including limits on the total number of cell generations and the difficulty of 
exchanging genetic material between cell lineages. In contrast, other differences, such as the 
large genome size, large population size, and rapid turnover, make the evolution of complex 
adaptations in cancer more likely.
EVIDENCE FOR ADAPTATIONS IN CANCER
Evolutionary adaptation occurs in any situation in which the conditions for natural selection 
are met (Bell 1997, p. 25). This is true for free-living organisms and for cancer cells alike. 
Natural selection results from the combination of (1) trait variation in a reproducing 
population (e.g., of cells), (2) inheritance of that variation across (cell) generations, and (3) 
variation in (cell) fitness correlated with heritable trait variation. All three of these sufficient 
conditions are met in neoplastic cells (Merlo et al. 2006). Evolution of adaptation through 
natural selection follows as a logical necessity. This is a precise description of the process, 
not merely a metaphor (pace Arnal et al. 2015).
In organismal biology, there has long been controversy over the power and limitations of the 
“adaptationist program” of searching for Darwinian adaptation as a way to generate 
hypotheses and guide research (Gould and Lewontin 1979; Mayr 1983), and some of this 
has parallels in cancer biology (Arnal et al. 2015). Does somatic evolution produce complex 
novelties, or merely remove or activate cell functions that are already encoded in the 
constitutive human genome? In general, we have information on the mutations and 
alterations that appear during somatic evolution, but know very little about the tempo and 
dynamics of their evolution.
Some of the convergent hallmark types of cancer only require a simple loss of molecular 
function, whereas others are complex and probably require multiple adaptations or extensive 
repurposing. For example, metastasis is a complex suite of cell behaviors, requiring 
detachment from the primary tumor, tissue invasion, intravasation into the blood vessels or 
lymphatic system, survival in that new environment, attachment to a new location, 
extravasation out of the blood vessels, growth in the new environment of that tissue with a 
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different hormonal and cytokine profile, and finally successful angiogenesis in that 
environment (Fidler 2003). Although the human genome includes the capacity to express all 
of those cell traits, their rediscovery and coordination may require selection for multiple 
genetic or epigenetic alterations.
Some of the clearest examples of adaptation in cancer come from acquired therapeutic 
resistance. All cytotoxic therapies and targeted therapies select for drug resistance (Pepper 
2011, 2012, 2016). As with the hallmarks, the molecular changes underlying acquired 
resistance often differ between tumors (Gottesman 2002), but the convergent trait of 
resistance is consistent across many cancer types and therapeutic agents (e.g., Azam et al. 
2003; Engelman et al. 2007; Murugaesu et al. 2015; reviewed by Pepper 2016).
Further evidence for evolutionary adaptation in cancer comes from the predictive value of 
cell genetic diversity, or “mosaicism,” in cancer progression. If there was no cell selection in 
neoplasms, if all somatic evolution was neutral, then the amount of diversity in a neoplasm 
would not be predictive of anything. It would only be informative of the past natural history 
of the neoplasm (Sottoriva et al. 2015; Williams et al. 2016). However, under somatic cell 
selection, diversity is critical, because it is the basis of fitness selection (Fernandez et al. 
2016). Empirically, higher genetic diversity within neoplasms does in fact predict both faster 
progression to malignancy and reduced patient survival time (Merlo et al. 2006, 2010; Mroz 
et al. 2015; Andor et al. 2016). The current interpretation of this pattern is that genetic 
diversity correlates with the likelihood that an adaptive mutation will appear, driving 
neoplastic progression (Merlo et al. 2006; Merlo and Maley 2010).
Although neutral evolution can generate diversity and may produce cells with the potential 
for adaptation, those cells become relevant only when they undergo clonal expansion in 
response to selective pressures from the microenvironment. For example, neoplastic cell 
populations may adapt only if they contain enough diversity to meet the challenges of 
metastasis or of therapy (Nguyen et al. 2016).
It is a well-known phenomenon in organismal evolution that mutations that are initially 
neutral become functionally relevant when the environment changes (Kimura 1983). 
Similarly, in somatic cell evolution, diversity predicts response to selection, thus drives the 
evolution first of malignancy, and later of acquired resistance to therapy (Andor et al. 2016; 
Nguyen et al. 2016).
Recent molecular evidence for cancer cell adaptation comes from examination of spatial 
heterogeneity in breast cancers (Lloyd et al. 2016). Evolutionary theory predicted that spatial 
variation of phenotypes could result from local variations in environmental factors that select 
for different phenotypic properties. For example, regions of low blood flow, which are 
commonly observed in tumor imaging, would select for tumors that are adapted to such 
conditions as reduced availability of substrate and blood-derived growth factors. Detailed 
analysis of spatial molecular heterogeneity in 10 clinical breast cancers showed a consistent 
regional distribution meeting this prediction, which supported the adaptive hypothesis 
(Lloyd et al. 2016).
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CONVERGENT CELLULAR EVOLUTION IS WHAT MAKES “CANCER” A 
MEANINGFUL (AND LETHAL) DISEASE CATEGORY
In biology, generally, some of the strongest evidence for adaptation comes from convergent 
evolution, in which different populations in similar environments evolve similar phenotypes 
as a result of similar selective pressures. Convergent evolution in cave fish is one classic 
example with recognized parallels to cancer cell evolution (Gatenby et al. 2011). Around the 
world, lakes inside caves hold hundreds of different populations of fish adapted to this 
specialized ecological niche by a consistent set of unusual traits we could call the “hallmarks 
of cave fish,” including loss of skin pigment and reduced eyesight (Fig. 2). Despite the trait 
similarities among these different species, genetic analysis reveals that each species evolved 
these “hallmarks of cave fish” independently, from genetically different founding 
populations, and that they still retain their genetic uniqueness. Such convergent trait 
evolution can only arise from a shared adaptive response to the same selective pressures, and 
such an adaptive response can only be driven by natural selection. Thus, convergent 
evolution in independent populations is a strong and reliable signature of adaptation through 
natural selection. This principle holds equally well both for populations of organisms and for 
populations of somatic cells becoming cancer in different hosts (Gatenby et al. 2011).
Without convergent evolution, there would be no similarities between tumors from different 
tissues, and so there would be no reason for us to categorize them together as the disease(s) 
we call “cancer.” In fact, we see the same phenotypes evolving over and over again, in 
entirely different types of cancers, in different hosts. We call these phenotypes the 
“hallmarks of cancer” (Hanahan and Weinberg 2011). They include the generation of growth 
signals, insensitivity to antigrowth signals, stabilization of telomeres, which allows 
unlimited replication, suppression of apoptosis, neo-angiogenesis, evasion of immune 
predation, and tissue invasion leading to metastasis. These are cancer hallmarks precisely for 
the reason that they each increase the fitness (survival and reproduction) of neoplastic cells 
and so evolve consistently, even from different genetic and phenotypic starting points (Fig. 
1). The ecological niche for all these cancers is that of an “endogenous parasite” (Charlton 
1996), meaning parasitic cells derived from normal cells but now competing with and 
exploiting them. The similarity across all cancers of this niche and its selective pressures 
explains why all cancers tend to generate similar cell traits even though each cancer can be 
as genetically unique as a species of cave fish (Fig. 2).
Somatic evolutionary adaptation not only is what makes “cancer” a meaningful disease 
category but also what makes cancer a malignant and deadly disease regardless of what 
tissue it arises in. Neoplasms that begin as benign growths soon outgrow their local 
resources, after which the only neoplastic cells that survive and proliferate are those that can 
acquire resources by invading the surrounding normal tissues. This constitutes a strong 
selective pressure, with malignant tissue invasion as the adaptive response (Aktipis et al. 
2012).
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ADAPTATIONIST THINKING PUSHES THE FRONTIERS OF CANCER 
RESEARCH
Beyond merely explaining why cancer is deadly, and refractory to treatment, adaptationist 
perspectives are also guiding current medical advances. The central problem in cancer 
medicine is that, “cancer is continuously adapting” (Willyard 2016), so that initially 
promising new therapeutics almost invariably fail in the face of acquired therapeutic 
resistance (Pepper 2016). The problem is not the specific mutations, which are highly 
variable and heterogeneous. Rather, the problem is adaptive evolution, and recognizing this 
has led some clinicians to refocus on “the possibility to track and treat evolution” (Willyard 
2016), by applying standard tools of evolutionary biology, such as phylogenetic 
reconstruction of ancestral lineages and evolutionary origins (Kostadinov et al. 2013; Jamal-
Hanjani et al. 2014; Willyard 2016) or mathematical models of fitness optimization through 
evolutionary adaptation (Misale et al. 2015; Enriquez-Navas et al. 2016; Lloyd et al. 2016).
Rather than just providing metaphors for thinking about the problem, adaptationist theory 
also provides mathematical models, such as evolutionary optimization on fitness landscapes, 
that can translate into new therapeutic strategies, such as the adaptive therapy regimens that 
have recently succeeded in animal models by avoiding acquired drug resistance and thereby 
prolonging progression-free survival (Enriquez-Navas et al. 2016; Schmidt 2016). To 
succeed, the emerging trend toward precision oncology must incorporate insights from 
ecology and adaptive evolution (Lloyd et al. 2015).
DO CANCER CELLS EVOLVE NOVEL TRAITS?
One of the classic conceptual challenges to adaptationist thinking that has reappeared in 
cancer biology (Arnal et al. 2015) is the question of novelty, or the distinction between new 
adaptations versus repurposed “exaptations” that originally served a different function 
(Gould and Lewontin 1979). Many traits of cancer are novel for the cell types in which the 
cancer arises but are normally expressed in other cell types or at other stages of 
development, from the same normal genome. In neoplasms, genes and traits that originally 
functioned in multicellularity are often “hijacked,” or repurposed for competition among 
cells. For example, the seemingly novel cancer phenotypes of rapid proliferation, motility, 
and tissue invasion often result from activation of functions that are normally expressed only 
by embryonic stem cells and are built into the normal human genome for that context 
(Brewer et al. 2009; Chen et al. 2015).
Another dramatic example of a complex cancer cell behavior that appears novel in its 
repurposed context of cancer progression is cell cannibalism, or consuming and digesting 
other cells (Lugini et al. 2006; Melendez-Lazo et al. 2015). This cell behavior is normal only 
for lymphocytes and is presumably enabled by normal human genes that are abnormally 
expressed in cancer cells.
Many other traits that evolve in cancers also are novel only in their abnormal context, such 
as shifting to a glycolytic metabolism in the presence of plentiful oxygen (the Warburg 
effect). Normal cells can shift to a glycolytic metabolism under oxygen deprivation, but 
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constitutive expression (the Warburg effect) is novel to cancer cells (Lunt and Vander Heiden 
2011).
The mechanisms of abnormal gene expression behind trait repurposing in cancer are 
gradually being revealed. Recent efforts to characterize the genetic regulatory networks in 
cancer cells have found extensive rewiring of those networks, relative to normal cells (Li et 
al. 2015b). Similarly, in organismal evolution, important trait changes have also occurred 
through changes in the regulation of genes (Wray 2007). In cancer, most of the detailed 
mechanisms remain to be described, because most cancer sequencing so far has exclusively 
focused on changes in coding regions, for the simple reason that we do not yet have good 
ways to identify regulatory regions and predict the consequences of mutations in those 
regions.
ADAPTATION THROUGH GENETIC NOVELTIES IN CANCER
In addition to abnormal gene expression, novel phenotypes can be generated by genetic (or 
epigenetic) novelties. Various mechanisms lead to novel genetic constructs and adaptive 
phenotypes in neoplastic cells. Most point mutations that transform protooncogenes into 
oncogenes are gain-of-function mutations, typically changing a conditional proliferative 
signal into a constant proliferative signal. Similarly, point mutations can generate 
adaptations by preventing drugs from binding to their target proteins (Milojkovic and 
Apperley 2009).
Although the size of the essential genome of human cancer cells is unknown, a comparison 
between the normal human genome (>20,000 genes) and a unicellular eukaryotic species 
such as yeast (~6300 genes) suggests the possibility of many nonessential genes in cancer 
cells. Those genes could constitute an extensive source of nonessential genes to evolve new 
functions, which could allow somatic evolution to generate novelties more quickly than in 
most unicellular evolution. In addition, genetic redundancy may allow cancer cells to 
tolerate deactivating deleterious genes, keeping active only those genes that benefit the 
fitness of a cell as a single-cell “endogenous parasite.” Taking into consideration the 
apparent proportion of non-essential genes in cancer, the proportion of random mutations 
that are advantageous to cancer cells is likely greater than the proportion of mutations that 
are advantageous in organismal evolution (Rajagopalan et al. 2003).
Many novel genetic constructs not present in normal cells have been described in cancer, 
including translocations, rearrangements, and gene fusions. The most famous of these is the 
BCR-ABL translocation in chronic myeloid leukemia, which fuses a promoter that is 
constitutively activated with a proliferative signal (Ren 2005). Such structural novelties often 
drive carcinogenesis (Kumar-Sinha et al. 2008; An et al. 2010; Greuber et al. 2013). An 
increase in retro-position rate in certain cancer types has been reported (Belancio et al. 2010, 
Helman et al. 2014; reviewed in Rodic and Burns 2013). This constitutes another potential 
source of novel genetic constructs, either mutating genes via insertion, changing the 
regulation of nearby genes, or generating gene duplications. Such a role in somatic cell 
evolution would parallel the known role of retroposition in organismal evolution (Xiao et al. 
2008).
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Evolution by gene duplication followed by divergence, or “neofunctionalization” (Ohno 
1970) is a classical model that explains the generation of new genetic loci in species 
evolution. Although new models have arisen since then (reviewed in Conant and Wolfe 
2008), all are based on two precepts: It is easier to generate new coding regions from 
preexisting ones; and relaxation of functional constraints is necessary to evolve new gene 
functions. Copy number amplification is common and relevant in somatic evolution, varying 
among cancer types (Zack et al. 2013), among tumors, and even within tumors (Gerlinger et 
al. 2014). Amplifications are even a predictor of prognosis in some cancers (Hieronymus et 
al. 2014; Li et al. 2015a). The possible role in somatic evolution of divergence after gene 
duplication will require further investigation.
Horizontal exchanges of genetic material or organelles may also contribute to the adaptive 
capacity of cancer cells. There is evidence that cancer cells can acquire new genes through 
fusion of cancer cells or fusion between cancer and normal cells (Duelli and Lazebnik 
2007). In addition, neoplastic cells can incorporate fragments of DNA from neighbors that 
have undergone apoptosis (Holmgren et al. 1999; Bergsmedh et al. 2001). Cancer cells can 
also acquire or replace their mitochondria from normal cells (Tan et al. 2015).
Each of these sources of genetic novelty can support the evolution of novel traits.
NEUTRAL EVOLUTION IN CANCER
Although we argue here for the central importance of natural selection and adaptation in 
cancer, selection is not the only mechanism of evolution in cancer. Indeed, both neutral and 
selected changes have been reported together in some cancers (Shpak et al. 2015). Recent 
work suggests that many cancers evolve with little evidence of natural selection after 
transformation to malignancy (Fig. 3) (Sottoriva et al. 2015; Williams et al. 2016). This may 
be because selection is relaxed after the process of carcinogenesis is complete and most 
intrinsic limits on cell survival and proliferation from the normal genome have already been 
removed. One extensive phylogeographic study of a liver tumor found no evidence of 
selection (Ling et al. 2015). However, it is important to note that this pattern of only neutral 
evolution is seen only in certain types of cancers. In contrast, evidence of convergent 
evolution and natural selection (even after transformation in some cases) has been found in 
many other cancers (Anderson et al. 2011; Gerlinger et al. 2012, 2014; Kovac et al. 2015; 
Yates et al. 2015).
CONCLUDING REMARKS
There is evidence for extensive evolutionary adaptation among cancer cells, and this process 
drives the convergent evolution that not only gives meaning to the category of “cancer,” but 
also is what makes cancer a malignant and deadly disease.
Despite this central role, other mechanisms of evolution are also at work in cancer. Neutral 
evolutionary theory provides a set of null models, which have recently been exploited to 
good effect for analyzing cancer evolution (Sottoriva et al. 2015). However, given all the 
hallmarks of cancers that evolve during neoplastic progression, and in particular the 
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evolution of malignancy and therapeutic resistance, we believe that adaptationist hypotheses 
are testable and useful, and also offer a crucial foundation for future medical advances.
Although evolutionary adaptation by somatic cells is different from organismal adaptation, it 
is central to cancer biology and needs to be understood. Natural selection should remain a 
key tool for generating hypotheses in cancer biology, and those hypotheses should be tested 
against alternatives including null models such as genetic drift.
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Figure 1. 
An example of convergent evolution in two species of cave fish descended from different 
ancestral populations. Amblyopsis rosae (top), and Astyanax mexicanus (bottom). Cave fish 
live in freshwater caves and have adapted to these specialized niches. Although these are 
different species, they have independently evolved similar phenotypes, such as loss of 
pigmentation and eyesight. (Images are under public domain, creative commons license.)
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Figure 2. 
Although tumors do not converge genetically, all typically converge on the same “hallmark” 
phenotypic traits. Here, we use a fitness landscape to illustrate convergent evolution of 
tumor phenotypes. The x- and y-axes (horizontal dimensions) represent two different 
quantitative traits (trait A and trait B), and the z-axis (vertical dimension) represents fitness. 
Fitness increases vertically and also scales in color from light blue (low fitness) to red (high 
fitness). We show two different neoplasms starting from different phenotypic states, depicted 
by the black and blue circles in the blue landscape valley. As neoplastic progression 
advances, these two tumors may follow different trajectories (indicated by the dotted lines) 
up the fitness peak. However, both tumors will converge on the same malignant phenotype 
(red fitness peak) showing the hallmarks of cancer.
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Figure 3. 
A schematic illustration of a phylogeny for somatic evolution in neoplastic cells over time 
(x-axis), starting from tumor initiation (far left). Neoplastic cell lineages accumulate somatic 
mutations during progression and eventually transformation to malignancy (far right). As 
described in the text, there may be multiple mechanisms of somatic evolution. Before 
malignancy, cell lineages may evolve by natural selection, in which certain clones have a 
fitness advantage. However, after transformation to malignancy, some neoplasms may evolve 
neutrally, in which clonal expansion is rapid (called the “big bang”) (Sottoriva et al. 2015), 
and most adaptation to the niche of the “endogenous parasite” is already completed.
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Table 1
Estimates and ranges for the parameters of somatic evolution in neoplasms
Parameter Estimates References
Point mutation rate 10−9–10−10 bp/cell division Knudson 1971; Wang et al. 2002; Araten et al. 
2005; Jones et al. 2008; Tomasetti et al. 2013
Amplification and deletion rate 10−4–10−5 gene/cell division Tlsty et al. 1989
Rate of loss of heterozygosity 10−4–10−6 gene/cell division de Nooijvan Dalen et al. 1998; Chan et al. 2001
CpG methylation rate 10−4 CpG/cell division Chan et al. 2001; Sottoriva et al. 2013
Total cell population size 1 cm3 of solid tumor: 108 cells
Multiple myeloma: 1012
Breast cancer: 107–1011
Lung cancer: 108–1012
Del Monte 2009; Sullivan and Salmon 1972; 
Friberg and Mattson 1997
Stem cell population sizea Multiple myeloma: 107–1010
Colorectal cancer: frequency 10−2–10−3
Hamburger and Salmon 1977a,b; Ricci-Vitiani et al. 
2007; Merlos-Suarez et al. 2011; Sottoriva et al. 
2013
Stem cell generation time Colorectal cancer in vitro: ~10 days
Colonic stem cells in vivo: ~7 days
Potten et al. 2003; Ricci-Vitiani et al. 2007
Clonal expansion rate 1.6 cm2 per year in Barrett’s esophagus Martinez et al. 2016
Selective coefficients Driver gene mean: 0.004
Probability of replacing a competitor cell: 62%–78%
Bozic et al. 2010; Vermeulen et al. 2013
Number of cell generations Colorectal cancer: 103–104 Yachida et al. 2010
Mutational burden Point mutations:
0.3–111/Mb
108 coding mutations across a tumor
Berger et al. 2012; Kandoth et al. 2013
Copy number alterations:
Median 40 per genome
Covering 33% of the genome
Ling et al. 2015; Zack et al. 2013
Translocations/genome:
Colorectal cancer: 0–10
Prostate cancer: 43–213
Breast cancer: 1–231
Cancer Genome Atlas 2012; Berger et al. 2011; 
Stephens et al. 2009
Time from initiation to diagnosis Colorectal cancer: 15–65 years
Pancreatic cancer: 50–60 years
Meza et al. 2008; Yachida et al. 2010
These parameters should be relevant to the clinical outcomes of all types of cancer, and so be universal biomarkers, applicable to all cancers. Most 
of these estimates are imprecise and future studies are needed to quantify and refine the estimates of the parameters of somatic evolution.
aCalculated from experimental observations of the frequency of putative cancer stem cells.
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